Search
Cisplatin Treatment Options
A collection of 1429 research studies where Cisplatin is the interventional treatment. These studies are located in the United States. Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.
985 - 996 of 1429
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Gemzar, Cisp, Sunitinib Urothelial Ca
Completed
The primary objective of this nonrandomized Phase II study is to evaluate the objective response rate (ORR, CR+PR) in patients with advanced/metastatic UC treated with the combination of gemcitabine, cisplatin, and sunitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2016
Locations: Arizona Oncology Associates, Tucson, Arizona +47 locations
Conditions: Urothelial Cancer
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Completed
The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2016
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +3 locations
Conditions: Bladder Cancer, Muscle-invasive Bladder Cancer
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
Completed
Multi-agent chemotherapy has value for patients with advanced pancreatic-biliary cancers leading to responses in a substantial minority and increasing survival. The use of the FOLFIRINOX regimen is limited by its' intensity and toxicity. Previous protocol and clinical experience within the University of Michigan Pancreatic Program leads to an expectation of tolerance and efficacy of the proposed regimen. Advantages of the proposed regimen relative to FOLFIRINOX include:
1. Substitution of gemci... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2016
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Pancreatic Cancer, Biliary Cancer
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Completed
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC). Patients will be randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and platinum (carboplatin/cisplatin) iv on Day 1 of e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2016
Locations: Not set, Huntsville, Alabama +68 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
Terminated
The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast tumor and allow you to preserve your breast. Sorafenib is a newer drug that targets blood vessel formation and may help the chemotherapy work better. Additionally, by receiving chemotherapy before surgery, we will be able to determine if your cancer is responsive to chemothe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2016
Locations: Grady Memorial Hospital, Atlanta, Georgia +2 locations
Conditions: Breast Cancer
Preoperative Cisplatin in Early Stage Breast Cancer
Completed
The purpose of this study is to find out what effects the preoperative therapy cisplatin will have on patients with early stage estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), or HER-2 negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2016
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Breast Cancer
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
Terminated
This is a multi-center, open-label, Phase 1b, dose escalation trial of Sym004 administered in combination with 1 of 3 platinum-doublets in subjects with Stage IV Non-Small Cell Lung Cancer (NSCLC).
The sponsor decided to discontinue the development of Sym004. Also the decision was made to discontinue the development of Sym004 in NSCLC indication. The decision to discontinue Sym004 in NSCLC was not related to any safety or efficacy findings regarding Sym004. As a result of the early discontinuat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2016
Locations: Please Contact U.S. Medical Information Located in, Rockland, Massachusetts +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Open Label, Phase I ZD6474 Head and Neck Cancer Study
Completed
The purpose of this study is to determine the maximum tolerated dose of ZD6474 given in combination with radiation or in combination with chemotherapy and radiation in patients with squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2016
Locations: Research Site, Denver, Colorado +3 locations
Conditions: Head and Neck Cancer
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Terminated
The purpose of this study is to investigate if the investigators can use a specific marker in the pancreatic tumor itself to determine which patients will benefit from receiving combination chemotherapy of gemcitabine and cisplatin after undergoing resection of a pancreatic cancer.
The investigators will also investigate if there is any benefit to receiving both chemotherapy drugs as opposed to only gemcitabine after undergoing complete resection of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2016
Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations
Conditions: Pancreatic Neoplasms, Pancreatic Cancer
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Completed
The purpose of this study is to determine the effectiveness of treatment with bevacizumab + cisplatin + cetuximab + IMRT. The doctor wishes to monitor patients for 2 years after the completion of study treatment to determine if they are cancer-free during that time. They also want to evaluate the side effects that patients experience with this treatment regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2016
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Head and Neck Cancer
Optimized Intensity Modulated Irradiation for Head and Neck Cancer
Completed
The purpose of this study is to test whether the use of advanced radiation therapy delivery techniques can spare a patient's normal tissue, including salivary glands, from radiation. This study is being done to try to reduce radiation side effects, especially mouth dryness, which happens with standard radiation methods. In order to reduce these side effects, other normal tissues may receive a different radiation dose (sometimes more) than what would have been received using standard radiation th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2016
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Head and Neck Cancer
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
Terminated
The standard treatment of muscle invasive bladder cancer is to administer chemotherapy for approximately 3 months then to have surgery to remove the bladder. Chemotherapy may reduce the size of the cancer in your bladder before surgery and can also help to reduce the chance that your bladder cancer will come back (metastasize) in other parts of your body after bladder surgery.
This study will involve testing cisplatin in lower weekly doses with gemcitabine.The purpose of this study is to test t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2016
Locations: Rhode Island Hospital (including Newport Hospital and East Greenwich), Providence, Rhode Island +1 locations
Conditions: Invasive Bladder Cancer, Bladder Cancer
985 - 996 of 1429